Human factors validation study of a disposable autoinjector (Bmab 1200 autoinjector) for subcutaneous delivery of Ustekinumab.
Ustekinumab is approved for treating moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. The Bmab 1200 autoinjector is a simple, two-step device for subcutaneous ustekinumab biosimilar delivery. This was an in vitro, nonclinical, simulated-use human fac…
Differential transcriptional and epigenetic signatures in CD4+ T cells separate enthesitis related and psoriatic juvenile idiopathic arthritis - a pilot study.
Juvenile idiopathic arthritis (JIA) is the most common musculoskeletal rheumatic disease affecting children. Following the currently used International League of Associations for Rheumatology (ILAR) classification, JIA encompasses seven clinically defined subtypes all of which share chronic inflamma…
Association between patient characteristics, demographics, and social determinants of health with treatment-refractory and complex-to-manage psoriatic arthritis.
Psoriatic arthritis (PsA) is a heterogeneous disease that presents challenges in both diagnosis and treatment. To address the disease burden, the Group of Research and Association of Psoriasis and Psoriatic Arthritis conducted surveys with patients to gain insights into patient experiences regarding…
A Case Series of Raynaud's Phenomenon in the Setting of Immune Checkpoint Inhibitors.
Although immune checkpoint inhibitors (ICIs) have improved oncological outcomes, they can cause a myriad of inflammatory conditions known as immune-related adverse events (irAEs). Raynaud's phenomenon (RP) is a rare rheumatologic irAE that may arise de novo or present as an exacerbation of preexisti…
Capsulectomy at Explant: Rethinking Spinal Cord Stimulator Infected Generator Pocket Management in the Immunocompromised-A Case Series.
Surgical site infections (SSI) associated with spinal cord stimulation (SCS) implants pose risks of morbidity, mortality, and increased healthcare costs. Immunocompromised patients are especially vulnerable due to impaired immune responses, delaying diagnosis and increasing complications. Current gu…
Functional characterization of genetic variants associated with response to tumor necrosis factor inhibitors in psoriatic arthritis patients.
Psoriatic arthritis is a chronic, progressive inflammatory disease associated with psoriasis, affecting joints, entheses, and the axial skeleton. Treatment options have evolved from broad immunosuppressive therapies to targeted biologic agents. These therapies are generally safe and effective, but p…
Bimekizumab efficacy across GRAPPA domains to 3 years in patients with psoriatic arthritis: a post hoc analysis of two phase 3 studies.
To evaluate the long-term efficacy of bimekizumab in patients with psoriatic arthritis (PsA) across the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) domains, PsA-related conditions, and comorbidities. Post hoc analysis of pooled data from BE OPTIMAL (NCT03895203; b…
One-Year Real-Life Data from Thai Patients with Moderate to Severe Plaque Psoriasis Treated with Secukinumab - Outcomes from the PROMPT Study.
Real-world data on secukinumab use in Thai patients with psoriasis is limited. This study evaluates its effectiveness and safety in routine clinical practice. The PROMPT study is an ongoing, multicenter, 2-year observational study involving patients with moderate to severe plaque psoriasis (PsO), ac…